Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

Bleeding Disorders

03 June 2008 CSL Behring Awards Global Grants to Next Generation of Coagulation Researchers

CSL Behring, a global leader in the protein biotherapeutics industry, today awarded CSL Behring - Prof. Heimburger Award grants to five young medical researchers at the Hemophilia 2008 World Congress of the World Federation of Hemophilia (WFH).

> Read More
29 February 2008 NHLBI Issues First U.S. von Willebrand Disease Clinical Practice Guidelines

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, today issued the first clinical guidelines in the United States for the diagnosis and management of von Willebrand Disease (VWD), the most common inherited bleeding disorder. The guidelines include recommendations on screening, diagnosis, disease management, and directions for future research. An extensive article on the guidelines is published online Feb. 29 in the journal Haemophilia.

> Read More
19 December 2007 CSL Behring Expands into Middle East Market with Haemate® P

CSL Behring today announced that Iran’s Ministry of Health and Medical Education (MOHME) has granted rights to the company to distribute Haemate P on an exclusive basis throughout Iran, beginning immediately.

> Read More
05 December 2007 CSL Behring study in animal models shows feasibility of developing a half-life extended recombinant FVIIa that retains biologic activity

CSL Behring today announced the results of a pre-clinical study that show for the first time it is feasible to genetically fuse Factor VIIa (FVIIa) to human albumin, prolonging the half-life of this therapeutic protein while retaining its biologic activity. In the study, which was presented at the American Society of Hematology 49th Annual Meeting and Exposition, the half-life of recombinant VIIa–albumin fusion protein (rVIIa-FP) was shown to be extended 6-to-9 fold compared to wild type rFVIIa. Additionally, rVIIa-FP demonstrated a biologic activity comparable to wild type rFVIIa.

> Read More
18 June 2007 CSL Behring Foundation Awards 10 Grants Totaling $487,000 to Benefit Bleeding Disorders Community

The CSL Behring Foundation for Research and Advancement of Patient Health has awarded more than $487,000 in funding for programs designed to benefit the bleeding disorders community. The grants will support a range of initiatives, including research projects and programs developed to educate and support patients.

> Read More
Page 18 of 19 First | Previous | Last

Share
LinkedIn Twitter Facebook Google+